Observational analysis revealed biomarkers and therapeutic targets in systemic lupus erythematosus, indicating new diagnostic tools may improve treatment outcomes.
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with poorly understood molecular mechanisms. This study investigated causal relationships between plasma proteins and SLE using two-sample Mendelian randomization analysis based on genome-wide association study data. Functional enrichment analyses Gene Ontology and Kyoto Encyclopedia of Genes and Genomes and protein-protein interaction network analysis identified apolipoprotein A2, MANSC domain-containing protein 1, and proteasome subunit beta 5 as key genes involved in glycoprotein metabolism and immune responses. Molecular docking simulations suggested meglumine and vorinostat as potential therapeutic candidates. A diagnostic nomogram model incorporating these genes demonstrated high predictive accuracy (area under the curve = 0.968). Single-cell RNA sequencing revealed that proteasome subunit beta 5 and MANSC domain-containing protein 1 were predominantly expressed in T cells and monocytes, implicating their roles in SLE-associated immune dysregulation. These findings highlight novel biomarkers, diagnostic tools, and therapeutic targets for SLE, advancing our understanding of its pathogenesis and treatment.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: